Illumina Inc (ILMN)

[ragraham]

Illumina's acquisition in September of BlueGnome makes more sense when you consider that millions of infertile women will soon get the biggest baby boost in a generation from preimplantation genetic diagnosis (PGD). This technology, which BlueGnome has pioneered, identifies a woman's healthiest embryos at in vitro fertilization (IVF) clinics. New studies show that PGD doubles the chances of a woman in her mid-30s to early-40s delivering a single, healthy baby per IVF attempt to nearly 60 percent. The current U.S. average is 31 percent. BlueGnome has developed technologies needed for a 24-hour PGD test. The full story is at:

https://sandiegobiotechnology.com/topics/5411/embryo-genetic-test-doubles-rate-of-one-in-vitro-fertilization-baby/